Revolution Medicines (MIL:1RVMD) Retained Earnings: €-3,443.61 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1RVMD Revolution Medicines Inc MIL:1RVMD
9 GF Score
Price €170.55
GF Value €0.41
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Revolution Medicines Retained Earnings?

Revolution Medicines MIL:1RVMD -1.39% 9 Retained Earnings is €-3,443.61 Mil as of Jun. 2026. GuruFocus rates MIL:1RVMD with a GF Score™ of 9/100 and a GF Value™ of €0.41 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Revolution Medicines's retained earnings for the quarter that ended in Jun. 2026 was €-3,443.61 Mil.

Revolution Medicines's quarterly retained earnings declined from Dec. 2025 (€-2,450.21 Mil) to Mar. 2026 (€-2,874.32 Mil) and declined from Mar. 2026 (€-2,874.32 Mil) to Jun. 2026 (€-3,443.61 Mil).

Revolution Medicines's annual retained earnings declined from Dec. 2023 (€-1,043.28 Mil) to Dec. 2024 (€-1,659.60 Mil) and declined from Dec. 2024 (€-1,659.60 Mil) to Dec. 2025 (€-2,450.21 Mil).


Revolution Medicines  (MIL:1RVMD) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Revolution Medicines Retained Earnings Historical Data

* Premium members only.

The historical data trend for Revolution Medicines's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revolution Medicines Retained Earnings Chart

Revolution Medicines Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only -400.58 -662.07 -1,043.28 -1,659.60 -2,450.21

Revolution Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,906.54 -2,133.59 -2,450.21 -2,874.32 -3,443.61
MIL:1RVMD
9GF Score
Revolution Medicines Inc MIL:1RVMD
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Revolution Medicines Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-3,443.61 Mil mean?
Revolution Medicines (MIL:1RVMD) has a Retained Earnings of €-3,443.61 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Revolution Medicines and its competitors.
Is Revolution Medicines' Retained Earnings too high?
Revolution Medicines' current Retained Earnings is €-3,443.61 Mil. Overall, Revolution Medicines has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Revolution Medicines' Retained Earnings compare to ALNY and ONC?
Revolution Medicines' Retained Earnings of €-3,443.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Revolution Medicines and its competitors. Revolution Medicines's current Retained Earnings is €-3,443.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revolution Medicines stock overvalued right now?
Based on GuruFocus' analysis, Revolution Medicines (MIL:1RVMD) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.41, compared to a current price of €170.55 — trading 41497.6% above its estimated fair value. The current Retained Earnings is €-3,443.61 Mil. Revolution Medicines' overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Revolution Medicines (MIL:1RVMD), the current Retained Earnings is €-3,443.61 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Revolution Medicines (MIL:1RVMD) Overvalued in 2026?

Based on GuruFocus' analysis, Revolution Medicines stock appears to be overvalued. The current stock price of €170.55 is trading 41497.6% above its estimated GF Value™ of €0.41. GuruFocus considers Revolution Medicines to be Significantly Overvalued.

Key valuation signals for MIL:1RVMD:

  • Retained Earnings: €-3,443.61 Mil
  • GF Value™: €0.41 vs. price of €170.55 (41497.6% above fair value)
  • GF Score™: 9/100 with 3 warning signs

No single metric tells the full story. See the MIL:1RVMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Revolution Medicines Business Description

Other Exchanges RVMD:USA42Z:Germany
Address 700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
9GF Score

Get the complete analysis for MIL:1RVMD

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€170.55
Price
€0.41
GF Value